PL376949A1 - Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego - Google Patents

Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego

Info

Publication number: PL376949A1
Authority: PL; Poland
Prior art keywords: calcium channel; methods; bladder disorders; treating non; channel modulators
Prior art date: 2002-12-20

Application number

PL376949A

Other languages

English (en)

Inventor

Karl Bruce Thor

Edward C. Burgard

Matthew Oliver Fraser

Original Assignee

Dynogen Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2003-12-19

Publication date

2006-01-09

2003-12-19 Application filed by Dynogen Pharmaceuticals, Inc. filed Critical Dynogen Pharmaceuticals, Inc.

2006-01-09 Publication of PL376949A1 publication Critical patent/PL376949A1/pl

Links

108090000312 Calcium Channels Proteins 0.000 title abstract 3
102000003922 Calcium Channels Human genes 0.000 title abstract 3
208000029162 bladder disease Diseases 0.000 title abstract 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 4
229960002870 gabapentin Drugs 0.000 abstract 2
206010020853 Hypertonic bladder Diseases 0.000 abstract 1
208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
-1 amino acid compounds Chemical class 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
208000020629 overactive bladder Diseases 0.000 abstract 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
229960001233 pregabalin Drugs 0.000 abstract 1
210000002700 urine Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Mobile Radio Communication Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL376949A 2002-12-20 2003-12-19 Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego PL376949A1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US43502102P	2002-12-20	2002-12-20
US48605703P	2003-07-10	2003-07-10
US52562303P	2003-11-26	2003-11-26

Publications (1)

Publication Number	Publication Date
PL376949A1 true PL376949A1 (pl)	2006-01-09

Family

ID=32686079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL376949A PL376949A1 (pl)	2002-12-20	2003-12-19	Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego

Country Status (13)

Country	Link
US (5)	US20040142034A1 (pl)
EP (1)	EP1480631B1 (pl)
JP (1)	JP2006511624A (pl)
KR (1)	KR20050084445A (pl)
AT (1)	ATE368456T1 (pl)
AU (2)	AU2003301184A1 (pl)
BR (1)	BR0317606A (pl)
CA (1)	CA2510292A1 (pl)
DE (1)	DE60315258T2 (pl)
ES (1)	ES2288641T3 (pl)
MX (1)	MXPA05006656A (pl)
PL (1)	PL376949A1 (pl)
WO (1)	WO2004058168A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040180958A1 (en) *	2002-12-13	2004-09-16	Taylor Charles Price	Method of treatment
JP2006511606A (ja)	2002-12-13	2006-04-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	下部尿路症状を治療するα−２−δリガンド
CA2510292A1 (en) *	2002-12-20	2004-07-15	Dynogen Pharmaceuticals, Inc.	Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
JP2006520799A (ja)	2003-03-21	2006-09-14	ダイノジェンファーマシューティカルズ，インコーポレイテッド	平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
US20040248979A1 (en) *	2003-06-03	2004-12-09	Dynogen Pharmaceuticals, Inc.	Method of treating lower urinary tract disorders
US7838029B1 (en) *	2003-07-31	2010-11-23	Watson Laboratories, Inc.	Mirtazapine solid dosage forms
US7390503B1 (en)	2003-08-22	2008-06-24	Barr Laboratories, Inc.	Ondansetron orally disintegrating tablets
EP1670451A4 (en) *	2003-09-11	2009-10-21	Xenoport Inc	TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
US8790696B2 (en)	2005-05-20	2014-07-29	Omeros Corporation	Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
WO2007005780A2 (en) *	2005-07-01	2007-01-11	Dynogen Pharmaceuticals, Inc.	Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EA017171B1 (ru)	2006-12-22	2012-10-30	Рекордати Айерленд Лимитед	КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
US9220837B2 (en)	2007-03-19	2015-12-29	Insuline Medical Ltd.	Method and device for drug delivery
WO2009081262A1 (en)	2007-12-18	2009-07-02	Insuline Medical Ltd.	Drug delivery device with sensor for closed-loop operation
RU2481128C2 (ru)	2007-03-19	2013-05-10	Инсьюлин Медикал Лтд.	Устройство для доставки лекарственного средства
US8622991B2 (en)	2007-03-19	2014-01-07	Insuline Medical Ltd.	Method and device for drug delivery
EP2355758A2 (en)	2008-11-07	2011-08-17	Insuline Medical Ltd.	Device and method for drug delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US18061A (en) *		1857-08-25		Island
US32235A (en) *		1861-04-30		mccormick
US45662A (en) *		1864-12-27		Improvement in supporters for artificial legs
US91159A (en) *		1869-06-08		Improved lifting-device for drop-presses and hammers
US55109A (en) *		1866-05-29		Improvement in screw-wrenches
US5180715A (en) *	1980-11-17	1993-01-19	The Regents Of The University Of California	Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) *	1989-01-27	1992-05-26	Immunolytics, Inc.	Method for treating benign prostatic hypertrophy
DE3928183A1 (de) *	1989-08-25	1991-02-28	Goedecke Ag	Lactamfreie cyclische aminosaeuren
WO1995009167A1 (fr) *	1993-09-30	1995-04-06	Tokyo Tanabe Company Limited	Derive d'indoline et antagoniste du recepteur 5-ht3 contenant ce derive et utilise comme ingredient actif
US5698549A (en) *	1994-05-12	1997-12-16	Uva Patent Foundation	Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) *	1995-05-22	1999-06-15	Alza Corporation	Dosage form and method for treating incontinence
DE19523868A1 (de) *	1995-06-30	1997-01-02	Huels Chemische Werke Ag	Verfahren zur Herstellung von Cyclopropanamin
US5610136A (en) *	1996-01-30	1997-03-11	Milkhaus Laboratory, Inc.	Method for treatment of benign prostatic hypertrophy
US5738873A (en) *	1996-09-27	1998-04-14	Herman Bleiweiss	Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) *	1996-12-24	2001-07-03	Teva Pharmaceutical Industries Ltd.	Preparation of gabapentin
US6150396A (en) *	1997-03-07	2000-11-21	Eli Lilly And Company	Methods of treating or preventing interstitial cystitis
US6090856A (en) *	1997-04-11	2000-07-18	Nippon Shinyaku Co., Ltd.	Remedies for frequent urination and urinary incontinence
US6329429B1 (en) *	1997-06-25	2001-12-11	Warner-Lambert Company	Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999020279A1 (en) *	1997-10-17	1999-04-29	Eli Lilly And Company	Potentiation of pharmaceuticals
FR2771093B1 (fr) *	1997-11-19	2000-01-21	Synthelabo	Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) *	1998-02-27	2001-11-20	Syntex (U.S.A.) Llc	2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) *	1998-04-24	2002-11-19	University Of Rochester	Antimuscarinic compounds and methods for treatment of bladder diseases
WO1999061424A1 (en) *	1998-05-26	1999-12-02	Warner-Lambert Company	Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
IL127129A (en) *	1998-11-18	2004-06-01	Ferring Bv	Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6329798B1 (en) *	1998-12-11	2001-12-11	Honeywell International Inc	Voltage controller for minimizing the utility power provided to a local load site having a local power source
AU779262B2 (en) *	1999-04-08	2005-01-13	Warner-Lambert Company	Method for the treatment of incontinence
WO2000067742A2 (en) *	1999-05-05	2000-11-16	Warner-Lambert Company	Use of gaba analogues for the modulation of substance p
CA2398199A1 (en) *	2000-01-28	2001-08-02	Asahi Kasei Kabushiki Kaisha	Novel therapeutic agents that use a .beta.3 agonist
DK1289364T3 (da) *	2000-06-16	2004-04-13	Teva Pharma	Stabil gapapentin som indeholder mere end 20 ppm chlorioner
JP2003535885A (ja) *	2000-06-16	2003-12-02	テバファーマシューティカルインダストリーズリミティド	制御された範囲内にｐＨを持つ安定なギャバペンチン
US7056951B2 (en) *	2000-09-26	2006-06-06	Mutual Pharmaceutical Co., Inc.	Stable solid dosage forms of amino acids and processes for producing same
HN2001000224A (es) *	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
EE200300249A (et) *	2000-11-30	2003-10-15	Pfizer Products Inc.	GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions
CA2440141A1 (en) *	2001-03-06	2002-09-12	Cellegy Pharmaceuticals, Inc.	Compounds and methods for the treatment of urogenital disorders
IL158359A0 (en) *	2001-05-25	2004-05-12	Warner Lambert Co	Liquid pharmaceutical composition
DE10146275A1 (de) *	2001-09-18	2003-04-24	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US6974818B2 (en) *	2002-03-01	2005-12-13	Euro-Celtique S.A.	1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
JP2006511606A (ja) *	2002-12-13	2006-04-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	下部尿路症状を治療するα−２−δリガンド
CA2510292A1 (en) *	2002-12-20	2004-07-15	Dynogen Pharmaceuticals, Inc.	Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
JP2006520799A (ja) *	2003-03-21	2006-09-14	ダイノジェンファーマシューティカルズ，インコーポレイテッド	平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
EP1539181B1 (en) *	2003-04-04	2007-06-27	Dynogen Pharmaceuticals Inc.	Method of treating lower urinary tract disorders
US7661614B2 (en) *	2004-09-10	2010-02-16	Fellowes Inc.	Shredder throat safety system

2003
- 2003-12-19 CA CA002510292A patent/CA2510292A1/en not_active Abandoned
- 2003-12-19 WO PCT/US2003/040730 patent/WO2004058168A2/en active IP Right Grant
- 2003-12-19 DE DE60315258T patent/DE60315258T2/de not_active Expired - Lifetime
- 2003-12-19 JP JP2005510027A patent/JP2006511624A/ja active Pending
- 2003-12-19 EP EP03814251A patent/EP1480631B1/en not_active Expired - Lifetime
- 2003-12-19 PL PL376949A patent/PL376949A1/pl not_active Application Discontinuation
- 2003-12-19 US US10/741,360 patent/US20040142034A1/en not_active Abandoned
- 2003-12-19 AT AT03814251T patent/ATE368456T1/de not_active IP Right Cessation
- 2003-12-19 BR BR0317606-1A patent/BR0317606A/pt not_active IP Right Cessation
- 2003-12-19 KR KR1020057011588A patent/KR20050084445A/ko not_active Application Discontinuation
- 2003-12-19 AU AU2003301184A patent/AU2003301184A1/en not_active Withdrawn
- 2003-12-19 MX MXPA05006656A patent/MXPA05006656A/es active IP Right Grant
- 2003-12-19 ES ES03814251T patent/ES2288641T3/es not_active Expired - Lifetime
2004
- 2004-08-18 US US10/920,483 patent/US20050054725A1/en not_active Abandoned
2005
- 2005-05-24 US US11/136,183 patent/US20050228049A1/en not_active Abandoned
2006
- 2006-04-07 US US11/400,554 patent/US20060188575A1/en not_active Abandoned
2009
- 2009-04-17 US US12/425,674 patent/US20090203792A1/en not_active Abandoned
2010
- 2010-02-26 AU AU2010200722A patent/AU2010200722A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2010200722A1 (en)	2010-03-18
KR20050084445A (ko)	2005-08-26
WO2004058168A2 (en)	2004-07-15
MXPA05006656A (es)	2006-02-22
DE60315258D1 (de)	2007-09-13
US20040142034A1 (en)	2004-07-22
ES2288641T3 (es)	2008-01-16
BR0317606A (pt)	2005-11-29
JP2006511624A (ja)	2006-04-06
WO2004058168B1 (en)	2004-11-11
AU2003301184A2 (en)	2004-07-22
EP1480631B1 (en)	2007-08-01
AU2003301184A1 (en)	2004-07-22
WO2004058168A3 (en)	2004-09-02
US20050228049A1 (en)	2005-10-13
ATE368456T1 (de)	2007-08-15
CA2510292A1 (en)	2004-07-15
US20060188575A1 (en)	2006-08-24
US20090203792A1 (en)	2009-08-13
DE60315258T2 (de)	2008-05-08
US20050054725A1 (en)	2005-03-10
EP1480631A4 (en)	2005-05-04
EP1480631A2 (en)	2004-12-01

Legal Events

Date	Code	Title	Description
2013-08-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL376949A1 (pl)	2006-01-09	Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego
PL1492519T3 (pl)	2007-04-30	Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich
AR048690A1 (es)	2006-05-17	Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos
EP2567705A3 (en)	2013-07-03	Methods of treating cognitive dysfunction by modulating brain energy metabolism
ZA976562B (en)	1998-02-03	Isobutylgaba and its derivatives for the treatment of pain.
EA200501497A1 (ru)	2006-06-30	АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2β-БЕЛКУ
WO2003082198A3 (en)	2004-12-23	Methods of treatment with lxr modulators
IL145763A0 (en)	2002-07-25	Method for the treatment of incontinence
WO2005000285A3 (en)	2005-03-03	METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
DK0994704T3 (da)	2005-10-03	Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
RS20060210A (en)	2008-09-29	Amino acids with affinity for the alpha2delta-protein
AU563291B2 (en)	1987-07-02	Gamma-vinyl gamma-aminobutyric acid composition
EA200501223A1 (ru)	2006-04-28	Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
EP1621193A3 (en)	2006-08-02	Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
BR0301960A (pt)	2004-08-24	Bactéria produtora da l-leucina, e, método para produção da l-leucina
DK0651821T3 (da)	1997-09-01	Enzymatisk resolvering af en racemisk blanding af stereospecifikke GABA-T-inhibitorer.
WO2004009636A3 (en)	2004-04-15	Gnrh modulator
ATE305778T1 (de)	2005-10-15	Behandlung von nierenkolik mit gaba-analogen
HN2003000108A (es)	2003-12-15	AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2o´